• Login
    • Join
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Manufacturing
    • Markets
    • Top 10 Orthopedic Device Firms
    • Buyers' Guide
    • Events
    • More
  • Magazine
  • News
  • Exclusives
  • Manufacturing
  • Markets
  • Top 10 Orthopedic Device Firms
  • Buyers' Guide
  • Events
  • Current & Past Issues
    Features
    Departments
    Columns
    Editorial
    Digital Edition
    Subscribe Now
    Advertise Now
    Editorial Guidelines
    eNewsletter Archive
    Top Features
    From Nitinol to Nanotubes: A Materials Science Roundtable

    In Good Repair: Trauma Technologies Under Review

    Anxious Undertones: A Review of 2019

    Automated Analysis Advantages for Part Validation

    Tried and True Metalworking
    Breaking News
    Certifications
    Clinical Trials
    Device Approvals & Patents
    Financial & Deals
    International
    Market Data & Trends
    OEM News
    People
    Product & Service Releases
    Products
    Quality, Recalls & Risk
    Regulatory & Legal
    Supplier & Contract Mfg.
    Live From Shows
    Top News & Features
    TriMed Closes Out FDA Warning Letter

    FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System

    OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application

    Tyber Medical Opens $8M Office and Manufacturing Facility

    FDA OKs Shoulder Surgery 3D Planner & Positioner
    3-D Printing/Additive Mfg.
    Assembly & Automation
    Biocompatibility & Testing
    Clean Room
    Coatings/Surface Modification
    Contract Manufacturing
    Design
    Extrusion
    Finishing
    Forging & Casting
    Instruments, Cases & Trays
    International/Offshoring
    Laser Processing
    Materials
    Machining & Tooling
    Molding
    Packaging & Sterilization
    Prototyping
    Research & Developement
    Software & Quality
    Staffing, Training & Prof. Dev.
    Supply Chain

    TriMed Closes Out FDA Warning Letter

    Sounding Board: Looking Back at 2019 and Gazing at 2020

    OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application

    Clinical Study of Cell Therapy for Disc Degeneration Clears Final Planned Safety Review

    3D-Printed Graftless Bone Transplants Go to Clinical Trials
    Biologics
    Bracing/Prosthetics
    Extremities
    Imaging
    Instruments
    Large Joint
    MIS/Robotics
    Spine/Neurology
    Trauma/Sports
    Top Markets
    Sounding Board: Looking Back at 2019 and Gazing at 2020

    Molybdenum-Rhenium Biomaterial: Something ‘MoRe’?

    New Exoskeleton Shoulders Rehab Burden for Stroke Patients

    Repairing Knee Cartilage Defects with the Patient's Own Cells

    Compamed 2019 Preview Report
    Companies
    Categories
    Company Capabilities
    White Papers
    Add New Company
    International Buyers Guide Companies
    Orthopedic Innovation Pty. Ltd.

    Nelson Laboratories LLC

    NN Life Sciences

    Tecomet

    Edge International/Supra Alloys
    Industry Events
    Webinars
    • Magazine
      • Current & Past Issues
      • Features
      • Editorial
      • Departments
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • Companies
      • Categories
      • Company Capabilities
      • White Papers
      • Add Your Company
    • Manufacturing
      • 3-D Printing/Additive Mfg.
      • Assembly & Automation
      • Biocompatibility & Testing
      • Clean Room
      • Coatings/Surface Modification
      • Contract Manufacturing
      • Design
      • Extrusion
      • Finishing
      • Forging & Casting
      • Instruments, Cases & Trays
      • International/Offshoring
      • Laser Processing
      • Materials
      • Machining & Tooling
      • Molding
      • Packaging & Sterilization
      • Prototyping
      • Research & Developement
      • Software & Quality
      • Staffing, Training & Prof. Dev.
      • Supply Chain
    • Markets
      • Biologics
      • Bracing/Prosthetics
      • Extremities
      • Imaging
      • Instruments
      • Large Joint
      • MIS/Robotics
      • Spine/Neurology
      • Trauma/Sports
    • Top 10 Orthopedic Device Firms
    • Online Exclusives
    • Slideshows
    • Videos
    • Webinars
    • Events
      • Industry Events
    • Live from Show Event
    • About Us
      • About Us
      • Contact Us
      • Privacy Policy
      • Terms of Use
      • Advertise With Us
    Features

    The ABCs of HCT/Ps

    Navigating the complex regulatory pathway of human cell and tissue products.

    The ABCs of HCT/Ps
    Related CONTENT
    • FDA Plans to Modernize 510(k) Program
    • Top 10 Findings from a Warning Letter Analysis
    • Global Prospects in Orthopedics
    • Material Matters: New Offerings for Orthopedic Technologies
    • An Embellished Coat for Bone Implants
    Lindsay Kleinwaks, Ph.D., Associate, Regulatory Affairs, MCRA05.23.19
    Human cells or tissues intended for implantation, transplantation, infusion, or transfer into the body are collectively regulated by the U.S. Food and Drug Administration (FDA) as “human cell, tissue, and cellular and tissue-based products.” Typically, biologic products are regulated with a Biologics Licensing Application (BLA), requiring premarket review and approval prior to marketing. However, a subset of these products are exempt from premarket review provided they meet established eligibility requirements. This subset is known as HCT/Ps, or 361-HCT/Ps.1 The FDA’s HCT/P regulation is multifaceted, and some of the eligibility criteria for exemption from premarket review are considered unclear by industry, leaving some areas of the regulation open to interpretation. Manufacturers have been using these vague definitions to justify biologics marketing under the HCT/P pathway since the approach is more attractive (faster and less costly) than the BLA regulatory pathway.

    To understand FDA’s current positioning on what constitutes a HCT/P, the agency has drafted and released a series of guidance documents to provide additional clarification of these concepts and definitions, complete with relevant examples. With the release of these guidance documents, however, comes an increase in FDA oversight of HCT/Ps with a grade period ending in November 2020. With the significant cost and time associated with the BLA pathway, manufacturers should revisit their product designations to assess whether they meet HCT/P requirements or if drug designation is required. This article is intended to help clarify FDA’s HCT/P requirements and explain how tightened regulation of these products will impact industry.

    HCT/P Regulation Overview
    HCT/Ps are regulated by 21 CFR, Parts 1270 and 1271, and the Public Health Service Act (PHS Act), Section 361. These regulations are designed to prevent the introduction, transmission, and spread of communicable disease through the transfer of cells and tissues between donors and recipients. Under these regulations, infectious disease testing, donor screening, and record-keeping are required for all cellular and tissue products.1

    Per 21 CFR 1271, regulation of HCT/Ps requires the establishment register with FDA (Form 3356) with annual renewal and a filed listing of all HCT/P products manufactured. To comply with the regulation, HCT/Ps must undergo donor screening and testing for communicable disease, and manufacturers must follow current Good Tissue Practices (cGTP). Due to their nature, additional adverse reaction reporting requirements apply, along with stringent HCT/P product labeling mandates.2 One of the key benefits of the HCT/P regulatory pathway is that it allows manufacturers to self-designate and does not require FDA premarket review before product commercialization.2 This premarket review exemption, however, leaves the manufacturer responsible for maintaining the proper internal documentation demonstrating its product meets all HCT/P regulatory pathway criteria. This documentation will likely be reviewed by FDA as part of any facility audits.

    Products meeting the criteria established in 21 CFR 1271 are subject to regulation by the PHS Act, Section 361. Products not meeting HCT/P requirements and not qualifying for any exceptions outlined in 21 CFR 1271(15) are regulated as a drug, device, and/or biological product under the Food, Drug and Cosmetic Act and/or PHS Act, Section 351.1 This pathway requires clinical studies and BLA submission, which substantially increase the time and cost required to market the product. Compared with HCT/P directives, BLA applications require substantial safety and efficacy evidence through bench, animal, and clinical trials. With FDA’s tiered, risk-based approach to HCT/P regulation, manufacturers are able to cut both costs and time to market.

    HCT/P Requirements
    HCT/Ps regulated by Section 361 of the PHS Act must meet the following requirements, established by 21 CFR 1271 (Chart).


     

     

    Through numerous guidance documents, FDA has defined several products that are considered HCT/Ps per the aforementioned criteria, in addition to several products that could be mistaken as HCT/Ps, but are ultimately excluded from regulation under Section 361.1

    HCT/P Interpretations
    FDA established the Tissue Reference Group (TRG) to help manufacturers determine product designation and correctly interpret the aforementioned criteria. A working group with drug, device, and biologics representatives, the TRG determines eligibility of novel cell and tissue products and publicizes its ruling. Additionally, FDA has issued several guidance documents to help industry interpret the criteria, including recent guidance addressing HCT/P manufacturing in light of new disease risks and technological advances, such as Zika and West Nile virus.3,4

    Some criteria used to define HCT/Ps in 21 CFR 1271 have been deemed by industry as unclear and ill-defined, leaving the requirements open to interpretation. FDA has provided explanations of these terms but has not yet issued a guidance that clearly defines “systemic effect” and “metabolic activity.” Consequently, manufacturers are able to interpret these specific criteria in their own way in product classifications.5 The FDA guidance “Regulatory Considerations of Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use (December 2017)” clarifies the agency’s position on “minimal manipulation” and “homologous use” in HCT/Ps.1

    Minimal Manipulation
    A key requirement in HCT/P regulation is that the product be “minimally manipulated,” and FDA interprets this term differently for structural and nonstructural tissues. In structural tissues like skin, bone, and adipose material, “minimally manipulated” denotes processing that maintains the tissue’s original characteristics—i.e., those relevant to the structure, such as strength and flexibility. Amniotic membrane (preserved in packaged sheets), for example, is considered an HCT/P by the FDA, as it is minimally manipulated but still retains its original relevant structural characteristics. Shaping harvested bone into dowels is also considered minimal manipulation because the original relevant characteristics have not been altered. Conversely, exposing bone to acid during demineralization is considered “more than minimal manipulation,” since the process alters the bone’s original relevant characteristics.1

    In nonstructural tissues such as hematopoietic stem cells and lymph nodes, minimal manipulation refers to processing that does not change the relevant biological characteristics of cells or tissues (those pertaining to cell function). An example of such manipulation would be hematopoetic stem cells that have been concentrated before transplantation. In this case, the processing has not altered the biological characteristics. Culturing these cells to drive differentiation, on the other hand, is considered “more than minimal manipulation.”1

    Since processing can potentially alter a product’s original characteristic as well as raise safety and efficacy concerns, manufacturing procedures and their impact should be considered at every step in production.

    Homologous Use
    The term “homologous use” has also lead to some confusion among manufacturers in determining the appropriate product classification. Homologous use refers to the repair, reconstruction, replacement, or supplementation of cells or tissues with an HCT/P that performs the same basic function(s) in the recipient as it does in the donor. FDA considers an HCT/P to be for homologous use when it repairs, reconstructs, replaces, or supplements recipient cells that are identical to the donor cells and performs one or more of the same basic functions performed by the donor cells. For instance, excised adipose tissue can be used to fill voids in the face or hands for cosmetic purposes and still maintain HCT/P status, since adipose tissue provides cushioning and support for other tissues. If the cell origin is not identical to the intended use in the recipient, the HCT/P must still perform one or more of the same basic functions. Case in point: A heart valve can replace another heart valve because the same basic function is preserved. Alternatively, transfer of hematopoetic stem cells from the bone marrow into an artery to limit ventricular remodeling is not considered homologous use, as this intended role is not a basic function of bone marrow cells.1

    FDA does not require the HCT/P be harvested from the same anatomic location as the recipient implantation. Bone, for example, can be harvested, demineralized, and used for the supplementation of recipient bone and still be considered a homologous use. Homologous use is critical for HCT/Ps, as non-homologous use can raise potential safety and efficacy concerns.1

    HCT/P Regulations – What’s to Come
    The HCT/P pathway is more appealing to companies, as it saves time and money (no premarket approval) as compared with the BLA regulatory route. As such, manufacturers have potentially been classifying and marketing products that may not fully meet HCT/P requirements. To address the potential safety and efficacy concerns resulting from the flux of these products into the U.S. market, FDA released a series of guidance documents that address the interpretation of HCT/P regulations. In a December 2017 guidance, FDA vowed over the next 36 months to “exercise enforcement discretion under limited conditions” regarding BLA premarket approval requirements for certain HCT/Ps.1 The FDA also promised to significantly increase HCT/P oversight to ensure all HCT/Ps meet all applicable requirements.

    The issuance of this guidance was soon followed by a press release by FDA in December 2018, noting that time is running out for manufacturers to come into compliance, with the November 2020 deadline quickly approaching. While what “enforcement discretion under limited conditions” will entail is still unknown, FDA followed the press release with a “To Whom It May Concern” letter issued to manufacturers producing stem cell products with vague, general indications in December 2018. As stated by former FDA Commissioner Scott Gottlieb within the press release, “The letters we’re issuing today…are a reminder that there’s a clear line between appropriate development of these products and practices that sidestep important regulatory controls needed to protect patients.”6 Overall, the purpose of both the guidance documents and press release is to open a channel of communication between HCT/P manufacturers and FDA, providing industry with FDA’s current position on HCT/P requirement interpretation and the best path forward to ensure compliance with the relevant regulations.

    The agency stated that it will be providing manufacturers ample time to determine if a marketing application is required for their products, providing 36 months before full enforcement is enacted. FDA also indicated which HCT/Ps are of most interest, stating that higher risk devices, such as those administered through intravenous injection or aerosol inhalation, will be the first products to come under review. By providing this information prior to the November 2020 deadline, manufacturers will have time to meet with and discuss any questions or concerns regarding product designation with FDA and plan accordingly. 

    References
    1. “Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use” FDA Guidance. December 2017.
    2. Title 21 of the Code of Federal Regulations, Part 1270 and 1271
    3. “Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry” FDA Guidance. Updated May 2018.
    4. “Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Living Donors of Human Cells, Tissues, and Cellular and Tissue-Based Product s (HCT/Ps) ; Guidance for Industry” FDA Guidance. Updated May 2017.
    5. Gadiock, P. “HCT/P Regulation – 351 vs 361 Products” (2017). Arent Fox, LLP. Presentation. 
    6. FDA News Release. “FDA sends warning to company for marketing dangerous unapproved stem cell products that put patients at risk and puts other stem cell firms, providers on notice.” December 20, 2018.

    Lindsay Kleinwaks, Ph.D., is a regulatory affairs associate at MCRA LLC, primarily focusing on developing regulatory strategies and submissions for the FDA, and international regulatory agencies. She has an extensive experience developing IDEs, 510(k)s, and clinical evaluation reports, with a focus in orthopedic devices. Kleinwaks also assists clients with understanding FDA’s interpretations of HCT/P designation requirements. She graduated from Drexel University with a doctorate degree in microbiology and immunology, with a concentration in molecular biology.
    Related Searches
    • orthopedic devices
    • orthopedic
    • running
    • manufacturing
    Suggested For You
    Technology Revision: Changes in Implant Manufacturing Technology Revision: Changes in Implant Manufacturing
    FDA OKs AMDT Holdings FDA OKs AMDT Holdings' SixFix Hexapod Fixator Device
    FDA Addresses Nitinol in Draft Guidance FDA Addresses Nitinol in Draft Guidance
    Brainlab Brainlab's Spine & Trauma 3D Navigation Software Recalled Over Misinterpretation Risk
    Pain Control Technology Embraces the Challenge to Reduce or Eliminate Opioids Pain Control Technology Embraces the Challenge to Reduce or Eliminate Opioids
    FDA Clears Additive Implants FDA Clears Additive Implants' 3D Printed SureMAX Cervical Spacer System
    CurvaFix Receives FDA 510(k) Clearance for CurvaFix Rodscrew CurvaFix Receives FDA 510(k) Clearance for CurvaFix Rodscrew
    FDA Commissioner Scott Gottlieb to Step Down FDA Commissioner Scott Gottlieb to Step Down
    FDA Issues Guidance on Brain-Computer Interfaces for Paralysis or Amputee Patients FDA Issues Guidance on Brain-Computer Interfaces for Paralysis or Amputee Patients
    Realizing the Promise of Pre-Validated Packaging Realizing the Promise of Pre-Validated Packaging
    Squeaky Clean: Orthopedic Device Packaging & Sterilization Squeaky Clean: Orthopedic Device Packaging & Sterilization
     Aziyo’s CanGaroo Envelope Cleared for Expanded Use With Neurostimulator Devices Aziyo’s CanGaroo Envelope Cleared for Expanded Use With Neurostimulator Devices
    FDA OKs Additive Orthopaedics FDA OKs Additive Orthopaedics' Patient-Specific 3D Printed Locking Lattice Plates
    An Embellished Coat for Bone Implants An Embellished Coat for Bone Implants
    Material Matters: New Offerings for Orthopedic Technologies Material Matters: New Offerings for Orthopedic Technologies

    Related Features

    • 3-D Printing/Additive Mfg. | Machining & Tooling | Materials | Molding
      From Nitinol to Nanotubes: A Materials Science Roundtable

      From Nitinol to Nanotubes: A Materials Science Roundtable

      While new materials are being made available, orthopedic device makers still lean on the well-established options for most new development.
      Mark Crawford, Contributing Writer 12.02.19

    • Biologics | Spine/Neurology | Trauma/Sports
      In Good Repair: Trauma Technologies Under Review

      In Good Repair: Trauma Technologies Under Review

      Novel technologies offer new approaches to fixing traumatic injuries when accidents happen.
      Sam Brusco, Associate Editor 12.02.19

    • MIS/Robotics | Packaging & Sterilization
      Anxious Undertones: A Review of 2019

      Anxious Undertones: A Review of 2019

      Despite a healthy U.S. economy and solid corporate growth, the medtech industry was wracked with worries in 2019.
      Michael Barbella, Managing Editor 12.02.19


    • Biocompatibility & Testing
      Automated Analysis Advantages for Part Validation

      Automated Analysis Advantages for Part Validation

      Accomplishing part fabrication validation can be better facilitated through the incorporation of automated protocols.
      Edward Jaeck, Vice President of Strategic Growth and Business Development, Lowell Inc. 09.17.19

    • Machining & Tooling
      Tried and True Metalworking

      Tried and True Metalworking

      While device manufacturers are curious about newer parts fabrication technologies, they still rely heavily on traditional machining providers.
      Mark Crawford, Contributing Writer 09.17.19

    • Biocompatibility & Testing
      Making the Grade: A Testing and Analysis Roundtable

      Making the Grade: A Testing and Analysis Roundtable

      This roundtable discussion examines the technological and regulatory factors affecting the third-party testing and analysis services industry.
      Sam Brusco, Associate Editor 09.17.19


    • Spine/Neurology
      Back in the Game: A Look at Spine Innovations

      Back in the Game: A Look at Spine Innovations

      An examination of truly unique technologies impacting the spinal sector.
      Michael Barbella, Managing Editor 09.17.19

    • Biologics | Bracing/Prosthetics | Extremities | Imaging | Instruments | Large Joint | MIS/Robotics | Spine/Neurology | Trauma/Sports
      The 2019 Top 10 Global Orthopedic Device Firms

      The 2019 Top 10 Global Orthopedic Device Firms

      Robotics and M&A continued to define the orthopedics industry in 2018.
      ODT Staff 08.14.19

    • Coatings/Surface Modification
      Supporting the Surface: A Look at a New Orthopedic Coating Technology

      Supporting the Surface: A Look at a New Orthopedic Coating Technology

      A novel ortho-coating could improve joint replacement outcomes.
      Vicki A. Barbur, Ph.D. and Anthony Duong, Ph.D., Battelle 08.14.19


    • Design | Research & Development
      Designing Complexity Simply

      Designing Complexity Simply

      New technologies and techniques allow orthopedic device developers to more effectively create advanced products.
      Mark Crawford, Contributing Writer 08.14.19

    • Bracing/Prosthetics | Imaging | Large Joint | Trauma/Sports
      Hidden Gems: 6 Orthopedic Technology Innovators of Note

      Hidden Gems: 6 Orthopedic Technology Innovators of Note

      These organizations are offering intriguing technologies to improve orthopedic care and, as such, have piqued the ODT editors’ interests.
      Sam Brusco, Sean Fenske, and Michael Barbella 08.14.19

    • Coatings/Surface Modification | Materials
      Face Value: An Overview of Surface Modification and Coatings

      Face Value: An Overview of Surface Modification and Coatings

      Orthopedic and spinal device surface treatments are necessary for a variety of aesthetic and functional improvements.
      Sam Brusco, Associate Editor 05.23.19

    • 3-D Printing/Additive Mfg. | Biologics | Extremities | Materials
      A Little Extreme: Factors Impacting the Extremities Implants Segment

      A Little Extreme: Factors Impacting the Extremities Implants Segment

      3D printing, surgical planning, and innovations that simplify procedures increasingly are shaping the global extremities market.
      Michael Barbella, Managing Editor 05.23.19

    • 3-D Printing/Additive Mfg. | Coatings/Surface Modification | Contract Manufacturing | Extremities | Finishing | Large Joint | Laser Processing | Machining & Tooling | Materials | Spine/Neurology
      Technology Revision: Changes in Implant Manufacturing

      Technology Revision: Changes in Implant Manufacturing

      Aspects of implant manufacturing are changing, enabling improved fabrication techniques with new material options.
      Mark Crawford, Contributing Writer 05.23.19

    • 3-D Printing/Additive Mfg. | Design | Prototyping
      Additive Manufacturing: A Tool for Driving Innovation

      Additive Manufacturing: A Tool for Driving Innovation

      Production applications for additive manufacturing are growing, but there are considerations to keep in mind.
      Tom Fripp, Founder and Managing Director, Addition Design & Research 03.29.19


    Breaking News
    • TriMed Closes Out FDA Warning Letter
    • FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System
    • OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application
    • Tyber Medical Opens $8M Office and Manufacturing Facility
    • FDA OKs Shoulder Surgery 3D Planner & Positioner
    View Breaking News >
    CURRENT ISSUE

    November/December 2019

    • From Nitinol to Nanotubes: A Materials Science Roundtable
    • In Good Repair: Trauma Technologies Under Review
    • Anxious Undertones: A Review of 2019
    • View More >
    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Deerland Obtains Certification from Australia’s Therapeutic Goods Administration
    OptiMSM Shown to Improve Hair & Nail Appearance and Condition
    DCC Acquires Contract Manufacturer Ion Laboratories
    Coatings World

    Latest Breaking News From Coatings World

    Beckers Group Announces Global Price Increase on Coil, Industrial Coatings
    Evonik, Wynca Celebrate Groundbreaking of New Fumed Silica Plant in Zhenjiang
    Personnel Changes in Corporate Communications, Government Relations at BASF
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    15-Year Tele-Critical Care Collabration Yields Significant ICU Improvement Results
    Prellis Biologics' New Tool Simplifies Complex Tissue Engineering
    InspireMD's CEO Steps Down
    Contract Pharma

    Latest Breaking News From Contract Pharma

    CatSci Expands Capabilities with Lab Expansion
    Smart Tags on Pills Set to Improve Supply Chain Security and Patient Adherence
    PCI Pharma Services Invests in Tredegar, UK Site
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Time Features 5 Best Beauty Inventions
    CES 2020 Preview - Innovation Award Honorees in Health & Wellness
    Star of E!'s Botched Gets Line Leaping Bunny Certified
    Happi

    Latest Breaking News From Happi

    Birchbox Partners with Buzzfeed
    Coty Strengthens Its Leadership
    Jennifer Garner Joins Virtue Labs
    Ink World

    Latest Breaking News From Ink World

    Smurfit Kappa, Wings for Aid Create Disaster Relief Packaging Solution
    ePac Flexible Packaging Expands into Asia Pacific Market
    United Carton Industries Company Invests in EFI Nozomi Corrugated Printer
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Luminer promotes Heather Bookman to prepress manager
    Materials Exchange launches to solve excess inventory issue
    Mark Andy joins forces with UPM Raflatac
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Simavita Set to License Sensor Technology in EU
    NDC Appoints President
    AATC Adds Two Scholarships
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    TriMed Closes Out FDA Warning Letter
    FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System
    OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    SEMI Releases Global Semiconductor Equipment Sales Forecast
    eMagin Corporation Announces Approximately $4.3 Million Order for Military Program
    CPI Supports Smart Food-labeling Project Set to Reduce Food Waste in 2020

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.